Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EPO Safety Review Will Be Closely Watched By Amgen, J&J And Roche

Executive Summary

Roche will refine its development program for the continuous erythropoeisis receptor activator (CERA) R-744 based on an upcoming FDA advisory committee discussion of EPO safety issues, Worldwide Pharmaceuticals Head William Burns said

You may also be interested in...



Amgen Wins Supreme Court Review Of EPO Securities Fraud Class Certification

The court will decide whether a party seeking class certification must show that a company’s alleged misrepresentations are material; investors claim Amgen misrepresented the safety of Aranesp and Epogen prior to a May 2004 FDA advisory committee meeting.

Aranesp/Procrit Trial Tumor Biopsy Collection Not Feasible, Cmte. Says

Amgen's and Johnson & Johnson's erythropoietin survival studies cannot logistically include a tumor biopsy component, FDA's Oncologic Drugs Advisory Committee said May 4

Aranesp/Procrit Trial Tumor Biopsy Collection Not Feasible, Cmte. Says

Amgen's and Johnson & Johnson's erythropoietin survival studies cannot logistically include a tumor biopsy component, FDA's Oncologic Drugs Advisory Committee said May 4

Related Content

UsernamePublicRestriction

Register

PS043806

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel